MA56001A - Formes de sel cristallin d'un inhibiteur de kinase - Google Patents
Formes de sel cristallin d'un inhibiteur de kinaseInfo
- Publication number
- MA56001A MA56001A MA056001A MA56001A MA56001A MA 56001 A MA56001 A MA 56001A MA 056001 A MA056001 A MA 056001A MA 56001 A MA56001 A MA 56001A MA 56001 A MA56001 A MA 56001A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962856404P | 2019-06-03 | 2019-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56001A true MA56001A (fr) | 2022-04-06 |
Family
ID=69160360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056001A MA56001A (fr) | 2019-06-03 | 2019-12-12 | Formes de sel cristallin d'un inhibiteur de kinase |
Country Status (19)
Country | Link |
---|---|
US (1) | US20230052703A1 (fr) |
EP (1) | EP3976587A1 (fr) |
JP (1) | JP2022535072A (fr) |
KR (1) | KR20220016117A (fr) |
CN (1) | CN113939503B (fr) |
AU (1) | AU2019449809A1 (fr) |
BR (1) | BR112021024300A2 (fr) |
CA (1) | CA3139148A1 (fr) |
CL (1) | CL2021003205A1 (fr) |
CO (1) | CO2021017343A2 (fr) |
CR (1) | CR20210616A (fr) |
DO (1) | DOP2021000236A (fr) |
GE (1) | GEP20247655B (fr) |
IL (1) | IL288484A (fr) |
MA (1) | MA56001A (fr) |
MX (1) | MX2021014773A (fr) |
PE (1) | PE20220962A1 (fr) |
SG (1) | SG11202111978VA (fr) |
WO (1) | WO2020247019A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3088200A1 (fr) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Composes destines au traitement de troubles dependant de la kinase |
GEP20247596B (en) * | 2018-12-13 | 2024-02-26 | Exelixis Inc A Delaware Corp | Crystalline forms and salt forms of a kinase inhibitor |
TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
CN118647603A (zh) | 2021-12-22 | 2024-09-13 | 埃克塞里艾克西斯公司 | 激酶抑制剂的结晶形式和盐形式 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2925655T3 (es) * | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
EP1871417B1 (fr) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Anticorps monoclonaux recombinés et antigènes correspondants contre les cancers du colon et du pancréas |
CA3139031A1 (fr) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation |
CA2910278C (fr) | 2013-05-02 | 2021-09-28 | Anaptysbio, Inc. | Anticorps diriges contre la proteine de mort programmee 1 (pd-1) |
US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
WO2018218233A1 (fr) * | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation |
CA3088200A1 (fr) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Composes destines au traitement de troubles dependant de la kinase |
CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 AU AU2019449809A patent/AU2019449809A1/en active Pending
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/fr active Application Filing
- 2019-12-12 KR KR1020217041796A patent/KR20220016117A/ko unknown
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 CA CA3139148A patent/CA3139148A1/fr active Pending
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 EP EP19836340.0A patent/EP3976587A1/fr active Pending
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 JP JP2021571744A patent/JP2022535072A/ja active Pending
-
2021
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN113939503B (zh) | 2024-05-07 |
WO2020247019A1 (fr) | 2020-12-10 |
SG11202111978VA (en) | 2021-11-29 |
AU2019449809A1 (en) | 2021-12-16 |
CO2021017343A2 (es) | 2022-01-17 |
MX2021014773A (es) | 2022-01-18 |
CL2021003205A1 (es) | 2022-09-30 |
CR20210616A (es) | 2022-03-22 |
JP2022535072A (ja) | 2022-08-04 |
IL288484A (en) | 2022-01-01 |
GEP20247655B (en) | 2024-08-26 |
KR20220016117A (ko) | 2022-02-08 |
EP3976587A1 (fr) | 2022-04-06 |
PE20220962A1 (es) | 2022-06-10 |
BR112021024300A2 (pt) | 2022-01-11 |
DOP2021000236A (es) | 2022-04-18 |
US20230052703A1 (en) | 2023-02-16 |
CA3139148A1 (fr) | 2020-12-10 |
CN113939503A (zh) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
MA42606A (fr) | Sels d'un inhibiteur de lsd1 | |
IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
IL289929A (en) | Crystal forms of cd73 inhibitor | |
IL287668A (en) | Crystalline forms of btk inhibitor | |
MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
PL3826982T3 (pl) | Zastosowanie podstawionych związków tiazolidynowych jako inhibitora nitryfikacji | |
MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
ZA202109183B (en) | Novel compounds for inhibition of janus kinase 1 | |
IL284226A (en) | Crystal structures of a TGFB inhibitor | |
MA53671A (fr) | Formes cristallines d'un agoniste du récepteur farnésoïde x | |
SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
MA54689A (fr) | Formes cristallines de 1-(1,2-diméthylpropyl)-n-éthyl-5-méthyl-n-pyridazin-4-yl-pyrazole-4-carboxamide | |
PL3891156T3 (pl) | Nowe krystaliczne formy inhibitora MCL-1, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne | |
IL285427A (en) | Crystal forms of jak2 inhibitor | |
MA53561A (fr) | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) | |
IL279953A (en) | Crystal forms of LTA4H inhibitor | |
MA53162A (fr) | Sel de xinafoate d'un composé inhibiteur de jak |